Roca Therapeutics
1 known investors
Roca Therapeutics develops non-invasive treatments for eye diseases, focusing on neovascular retinal diseases. The company's lead candidate RCT002 is a topical small molecule therapy targeting radiation maculopathy and diabetic macular edema.